HomeCompareCDMO vs ARCC

CDMO vs ARCC: Dividend Comparison 2026

CDMO yields 16.01% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARCC wins by $2.0K in total portfolio value· pulled ahead in Year 4
10 years
CDMO
CDMO
● Live price
16.01%
Share price
$12.49
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$1.79
Full CDMO calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — CDMO vs ARCC

📍 ARCC pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDMOARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDMO + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDMO pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDMO
Annual income on $10K today (after 15% tax)
$1,361.09/yr
After 10yr DRIP, annual income (after tax)
$1.52/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, CDMO beats the other by $0.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDMO + ARCC for your $10,000?

CDMO: 50%ARCC: 50%
100% ARCC50/50100% CDMO
Portfolio after 10yr
$23.5K
Annual income
$1.48/yr
Blended yield
0.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

CDMO
Analyst Ratings
1
Strong
8
Buy
1
Hold
Consensus: Buy
Price Target
$8.00
-35.9% upside vs current
Range: $8.00 — $8.00
Altman Z
-0.6
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDMO buys
0
ARCC buys
0
No recent congressional trades found for CDMO or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDMOARCC
Forward yield16.01%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%-50%
Portfolio after 10y$22.6K$24.5K
Annual income after 10y$1.79$1.16
Total dividends collected$1.7K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$8.00$21.88

Year-by-year: CDMO vs ARCC ($10,000, DRIP)

YearCDMO PortfolioCDMO Income/yrARCC PortfolioARCC Income/yrGap
1$11,501$800.64$11,381$541.15+$120.00CDMO
2$12,736$430.27$12,621$284.08+$115.00CDMO
3$13,850$222.66$13,827$145.31+$23.00CDMO
4← crossover$14,933$113.15$15,062$73.43$129.00ARCC
5$16,035$57.01$16,364$36.89$329.00ARCC
6$17,186$28.60$17,757$18.49$571.00ARCC
7$18,404$14.33$19,258$9.25$854.00ARCC
8$19,699$7.17$20,880$4.63$1.2KARCC
9$21,081$3.59$22,636$2.32$1.6KARCC
10$22,559$1.79$24,539$1.16$2.0KARCC

CDMO vs ARCC: Complete Analysis 2026

CDMOStock

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Full CDMO Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this CDMO vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDMO vs SCHDCDMO vs JEPICDMO vs OCDMO vs KOCDMO vs MAINCDMO vs HTGCCDMO vs GBDCCDMO vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.